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Summary
Objective: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor
blockers (ARBs) effectively interfere with the sympathetic nerve activity in patients
with left ventricular (LV) dysfunction. The aim of this study was to examine the
effect of ARBs on sympathetic nerve activity and baroreﬂex function in patients
with LV dysfunction already receiving ACE inhibitors.
Methods: Twenty patients with LV dysfunction already treated with ACE inhibitor
(enalapril 5mg/day) were randomly divided into two groups: treatment with
10mg/day enalapril (control group) or 5mg/day enalapril plus 80mg/day valsar-
tan (combination group). In both groups, resting muscle sympathetic nerve activity
(MSNA; microneurography), arterial baroreﬂex sensitivity, and cardiopulmonary
baroreﬂex sensitivity were measured at baseline and 4 weeks after the treatment.
Arterial baroreﬂexes were perturbed by phenylephrine method, and cardiopul-
monary baroreﬂexes were perturbed by lower body negative pressure (−10mmHg).
Results: Baseline characteristics in both groups were similar. Resting MSNA decreased
signiﬁcantly from 35.4± 10.8 to 26.4± 5.1 burst/min (p < 0.05), while arterial
baroreﬂex sensitivity improved signiﬁcantly from 6.0± 2.0 to 10.1± 2.6ms/mmHg
in the combination group. Moreover, cardiopulmonary baroreﬂex control of MSNA
improved signiﬁcantly from 15.8± 12.2 to 42.0± 26.7% (p < 0.05) in the combination
group. However, there were no signiﬁcant changes in arterial baroreﬂex sensitivity
and cardiopulmonary baroreﬂex of MSNA in the control group.
∗ Corresponding author at: Cardiovascular Center, CCU, Kansai Medical University, 2-3-1 Shinmachi, Hirakata City, Osaka,
apan 573-1191. Tel.: +81 72 804 2602; fax: +81 72 804 2894.
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ARB to ACE inhibitor treatment reduced sympathetic nerve
rterial and cardiopulmonary baroreﬂex sensitivity in patients
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cardiopulmonary baroreﬂex testing with low body
negative pressure were performed. The patients
were randomly assigned to two matched groups:172
Conclusion: Addition of
activity and augmented a
with LV dysfunction.
© 2008 Japanese Colleg
reserved.
Introduction
Neurohumoral excitatory state results from abnor-
mality of baroreﬂexes and reduced tonic restraint
of baroreﬂexes leads to neurohumoral excitation
[1]. Baroreceptor effort to restrain heart rate and
sympathetic nerve trafﬁc is markedly impaired in
patients with heart failure, and this impairment
is related to the increase in sympathetic burst
frequency [2,3]. Previous studies have suggested
that sympathetic activation in heart failure has a
baroreﬂex origin and that angiotensin II is respon-
sible for baroreﬂex dysfunction [4—8]. Indeed,
angiotensin-converting enzyme (ACE) inhibition
augments arterial and cardiopulmonary baroreﬂex
control of sympathetic nerve activity in patients
with heart failure [7]. However, plasma concentra-
tion of angiotensin II remains elevated in patients
with heart failure despite treatment with an ACE
inhibitor [9]. This elevation is explained, at least in
part, by the existence of non-ACE pathways that
convert angiotensin I to angiotensin II [10]. Fur-
thermore, ACE inhibition leads to accumulation of
bradykinin, which releases noradrenaline as a reﬂex
response [11]. Angiotensin II type 1 (AT1) receptors
mediate most of the harmful effects of angiotensin
II, and angiotensin II receptor antagonists (ARBs)
block AT1 receptor-mediated effects directly at the
receptor site. Therefore, addition of ARB to ACE
inhibitor therapy may result in a more complete
suppression of the sympathetic nerve activity in
patients with heart failure. However, the effective-
ness of combined ARB and ACE inhibitor therapy
remains to be deﬁned.
In this study, we examined the effect of the ARB
valsartan on arterial and cardiopulmonary barore-
ﬂex sensitivity in patients with left ventricular (LV)
dysfunction already receiving ACE inhibitor. In addi-
tion, we simultaneously examined the change in
sympathetic nerve activity by directly recording
muscle sympathetic nerve activity (MSNA) using
microneurography after combined therapy.
MethodsPatient population
Our study was performed in 20 patients (16 men and
4 women, mean age 59± 9 years) with idiopathic
1
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ilated cardiomyopathy (7 patients) or ischemic
ardiomyopathy (13 patients). All the patients
eceived ACE inhibitors (enalapril 5mg) for more
han 6 months and echocardiographic LV ejection
raction was 35.7± 7.5% with New York Heart Asso-
iation class I—III. The etiology of LV dysfunction
as assessed in all patients by accurate diagnos-
ic evaluation including coronary angiography. All
he patients included in this study were normoten-
ive and in sinus rhythm. No patient had a history
f myocardial infarction in the 6 months preceding
he study, postinfarction angina, critical arrhyth-
ia, uncontrolled congestive heart failure, clinical
r echocardiographic evidence of valvular heart
isease, renal insufﬁciency, diabetes mellitus, or
ny other condition known to affect the auto-
omic nervous system. Calcium antagonists and
eta blockers were given according to clinical needs
calcium antagonists in 4 patients, beta blockers in
1 patients). In this study, 9 patients did not have
eta blockers, 2 patients with bronchial asthma and
patients with suspected coronary spasms. The
emaining 5 patients did not have beta blockers
ecause of patent coronary arteries with negative
xercise test results. All medications were kept
onstant throughout the study. Patients gave writ-
en informed consent and the study was approved
y the Ethics Committee of Kansai Medical Univer-
ity.
tudy protocol
he patients were taken to the laboratory in
he morning after a light breakfast. They were
laced in a supine position and ﬁtted with elec-
rocardiogram lead, an arterial blood pressure
ecording device, and a microelectrode for record-
ng of MSNA. After 30min, a venous blood sample
as obtained, and blood pressure was measured
hree times by mercury sphygmomanometer and
as averaged. Resting MSNA measurement, arte-
ial baroreﬂex testing with phenylephrine, and0 patients received oral ACE inhibitor, enalapril,
t a dosage of 10mg once a day (control group),
hile 10 patients received enalapril at a dosage
f 5mg and ARB, valsartan, at a dosage of 80mg
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rympathoinhibitory effect of valsartan
combination group). After 4 weeks, all the patients
ere asked to return to the laboratory and were
eevaluated according to the procedure adopted at
he ﬁrst visit. All patients tolerated the treatment
ell throughout the 4-week span.
ympathetic nerve trafﬁc
ultiunit recordings of efferent postganglionic sym-
athetic nerve activity to the muscle bed were
btained with a tungsten microelectrode with a tip
iameter of a few microns inserted into a mus-
le fascicle of the peroneal nerve posterior to the
bular head. A low-impedance reference electrode
as inserted subcutaneously a few centimeters
way. Details of the nerve recording technique and
riteria for MSNA have been reported previously
12]. The original nerve signal was ampliﬁed with
gain of 50,000 and fed through a band-pass ﬁl-
er with a band width of 500—3000Hz and then
hrough an integrating network with a time con-
tant of 0.1 s to obtain a mean voltage display of
erve activity. Integrated nerve activity was mon-
tored by a loudspeaker, displayed on a storage
scilloscope (VC-6725, Hitachi, Miyagi, Japan), and
tored on a personal computer (Machintos) for later
nalysis (AcqKnowledge III for the MP100WS). Sym-
athetic bursts were identiﬁed by visual inspection
f the integrated neurogram. MSNA was quantiﬁed
s bursts per minute (bursts/min).
rterial baroreﬂex sensitivity assessment
tudies were carried out in the morning after
0min of supine rest. Arterial baroreﬂex sensitivity
as assessed by the phenylephrine bolus method.
rterial blood pressure (Jentow 7700; Colin Cor-
oration, Komaki, Japan) and heart rate were
ontinuously recorded. Phenylephrine (2—3g/kg)
as injected intravenously to disturb systolic arte-
ial pressure 15—30 mmHg by at least three bolus
njections separated by 10-min intervals. The R—R
ntervals were plotted against the preceding arte-
ial systolic pressure and a linear regression was
btained by the points included between the begin-
ing and the end of the ﬁrst statistically signiﬁcant
hange in systolic arterial pressure. Only regression
ines with a correlation coefﬁcient 0.90 or that
ith p < 0.05 were used, and the mean of at least
hree measurements was calculated.ardiopulmonary baroreﬂex control of
SNA assessment
he method described by Dibner-Dunlap et al. [7]
as used to evaluate the cardiopulmonary barore-
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ex function. Patients were sealed at the level of
he iliac crests in a chamber designed for admin-
stering low body negative pressure, and ﬁtted
ith ECG leads, non-invasive arterial blood pres-
ure recording devices, and microelectrodes for
SNA recording. A catheter was inserted from the
ntecubital vein of the right arm and was placed
ear the right atrium for the measurement of cen-
ral venous pressure and for the administration of
rugs. After the catheter was inserted, patients
ested in a supine position for 30min. Cardiopul-
onary baroreﬂex provocation was performed by
pplying low body negative pressure to −10mmHg.
ardiopulmonary baroreﬂex control of sympathetic
erve activity was determined by calculating the
hange in MSNA from 1min preceding low body neg-
tive pressure to the second minute during low
ody negative pressure. Percent change in MSNA
as used to account for the different starting values
etween the two groups.
emodynamic measurements
emodynamic measurements were performed at
est, after bolus infusion of phenylephrine, and
uring low body negative pressure. Arterial blood
ressure was obtained non-invasively via a photo-
lethysmographic transducer (Jentow 7700; Colin
orporation) and continuously recorded. Heart rate
as derived from continuously monitored elec-
rocardiography. Respiration was monitored by a
train-gauge pneumography positioned at the mid-
hest level. Central venous pressure was measured
y a catheter connected with a transducer (Bax-
er Health Care Corp, Irvine, CA, USA) positioned
t the midchest level. Left ventricular ejection
raction was obtained echocardiographically (Sonos
500; Philips Medical Systems, Andover, MA, USA)
y a single operator unaware of the experimental
esign. End-diastolic and end-systolic LV volumes
ere derived using Simpson’s rule by manual endo-
ardial tracing of the apical four-chamber and
pical two-chamber views, and LV ejection frac-
ion was calculated as 100× {(LV end-diastolic
olume− LV end-systolic volume)/LV end-diastolic
olume}}.
eurohumoral variables
lood samples for plasma noradrenaline, plasma
enin activity, and plasma angiotensin II con-
entrations were obtained from a line in the
ntecubital vein before therapy and after 4 weeks
n treatment. Plasma noradrenaline was measured
y high performance liquid chromatography with
lectrochemical detection. Plasma renin activity
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Table 1 Clinical characteristics.
Control group (n = 10) Combination group (n = 10) p-Value
Age (years) 59.1± 7.7 57.9± 9.7 0.80
Male (%) 8 (80) 8 (80) 1.00
LVEF (%) 36.8± 6.7 34.5± 7.7 0.70
NYHA class (%)
I 3 (30) 3 (30) 0.58
II 5 (50) 4 (40) 0.57
III 2 (20) 3 (30) 0.48
IHD (%) 7 (70) 6 (60) 0.64
Hypertension (%) 3 (30) 4 (40) 0.64
Hyperlipidemia (%) 2 (20) 2 (20) 0.48
Diabetes mellitus (%) 0 0
Medications
Beta-blocker (%) 6 (60) 5 (50) 0.65
Calcium antagonists (%) 1 (10) 3 (30) 0.26
Diuretics (%) 2 (20) 3 (30) 0.26
jecti
D
D
u
g
C
v
t
o
b
t±S.D. or percentage of patients; LV, left ventricular; LVEF, LV e
heart disease.
and plasma angiotensin II concentrations were
measured by radioimmunoassay [13,14]. Plasma
samples were applied to the phenylsilyl silica
cartridge conditioned with methanol and Milli-
Q water, and then eluted with methanol. After
the eluent was evaporated, the dried residue
was resuspended with mobile phase (310ml/l of
acetonitrile and 2ml/l heptaﬂuorobutyric acid).
For high-performance liquid chromatography, the
Waters 625 LC system equipped with a model
600E system controller, 625 pump, 484 UV detec-
tor, and autoinjector was used. Separation of
angiotensin II-related peptides was performed at
◦38 C with a Nucleosil C18 (5m; 4.6mm× 250mm)
reversed-phase column with a ﬂow rate of 1ml/min
using the mobile phase. The eluate was monitored
at 215 nm, evaporated and resuspended with a
radioimmunoassay buffer.
R
C
T
v
Table 2 Hemodynamics and neurohormonal variables.
Control group
Before TX After TX p-Va
Blood pressure (mmHg)
Systolic 123.0 ± 10.2 125.1 ± 7.5 0.58
Diastolic 68.9 ± 6.5 67.5 ± 5.5 0.40
HR (bpm) 64.4 ± 9.9 64.1 ± 10.3 0.91
NE (pg/ml) 304.4 ± 103.8 292.2 ± 92.2 0.56
Renin (ng/ml) 9.2 ± 22.3 8.8 ± 16.4 0.96
Ang II (pg/ml) 26.9 ± 46.7 34.8 ± 44.6 0.54
BNP (pg/ml) 42.6 ± 35.4 42.5 ± 37.8 0.95
Data are mean± S.D. TX, treatment; HR, heart rate; NE, norepinepon fraction; NYHA, New York Heart Association; IHD, ischemic
ata analysis
ata were analyzed by a single investigator. Val-
es from individual subjects were averaged for the
roup as a whole and expressed as mean± S.D.
omparisons between data obtained at reference
alue and after 4 weeks on treatment were made by
wo-way ANOVA. The two-tailed t-test for unpaired
bservations was used to identify the difference
etween the two groups. A p-value of p < 0.05 was
aken as indicating statistical signiﬁcance.
esultslinical characteristics are outlined in Table 1.
here were no signiﬁcant differences in the clinical
ariables between the two groups.
Combination group
lue Before TX After TX p-Value
118.6 ± 11.7 114.9 ± 9.8 0.19
67.3 ± 7.5 62.7 ± 12.3 0.18
63.5 ± 6.0 63.4 ± 5.6 0.92
338.4 ± 165.4 279.0 ± 122.1 0.25
5.9 ± 6.8 21.3 ± 29.2 0.15
27.9 ± 36.2 60.9 ± 82.6 0.32
26.4 ± 24.0 23.9 ± 24.9 0.74
hrine; Ang, angiotensin; BNP, brain natriuretic peptide.
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pigure 1 Changes in resting MSNA before and after 4 we
esting MSNA and measured variables
chocardiographic, hemodynamic, and neuro-
umoral changes are summarized in Fig. 1,
ables 2 and 3. At baseline, there were no
igniﬁcant differences in echocardiographic, hemo-
ynamic, and neurohumoral variables between
he two groups. The echocardiographic data did
ot change before and after treatment in both
roups. Plasma noradrenaline did not change
igniﬁcantly after 4 weeks in either group, but
SNA reduced signiﬁcantly from 35.4± 10.8 to
6.4± 5.1 bursts/min in the combination group
p < 0.05). This was in contrast to that observed
n the control group (from 42.5± 9.1 to 41.4± 8.4
ursts/min, p = 0.55), which showed no substantial
lteration over the 4-week period. Plasma renin
ctivity and angiotensin II concentrations did not
t
a
s
a
Figure 2 Change in arterial baroreﬂex sensitivn one patient. MSNA, muscle sympathetic nerve activity.
hange signiﬁcantly after 4 weeks on treatment in
ither group.
rterial baroreﬂex sensitivity
ig. 2 shows the changes in arterial barore-
ex sensitivity (before and after 4 weeks) in
he two groups. No serious adverse event was
bserved during phenylephrine infusion. In the con-
rol group, phenylephrine (2—3g/kg, 50—70g)
as administrated intravenously to produce a rise in
ystolic pressure of 25± 2mmHg, while 2—3g/kg
40—70g) of phenylephrine produced a systolic
ressure change of 27± 3mmHg in the combina-
ion group. The same dose of phenylephrine was
dministered 4 weeks later resulting in a pres-
ure change of 26± 3mmHg in the control group
nd 27± 4mmHg in the combination group. At
ity. ACE, angiotensin-converting enzyme.
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Table 3 Changes in echocardiographic variables.
Control group Combination group
Before TX After TX p-Value Before TX After TX p-Value
LVDd 52.9 ± 6.0 53.2 ± 3.8 0.85 54.9 ± 3.0 54.4 ± 3.9 0.15
LVDs 37.2 ± 2.6 37.2 ± 6.1 0.99 40.1 ± 3.9 40.9 ± 5.6 0.92
LAD 38.1 ± 2.5 37.3 ± 2.9 0.46 36.1 ± 4.4 36.3 ± 4.5 0.70
IVS 9.3 ± 1.6 9.7 ± 1.5 0.14 8.6 ± 1.6 8.6 ± 1.6 0.92
LVPW 9.8 ± 1.0 9.8 ± 1.0 0.95 8.6 ± 1.5 8.8 ± 1.7 0.56
Degree of MR 0.7 ± 0.5 0.7 ± 0.5 0.59 0.9 ± 0.7 0.9 ± 0.7 0.69
Data are mean± S.D. TX, treatment; LV, left ventricular; LVDd, LV di
dimension; IVS, intraventricular septum; LVPW, LV posterior wall; M
baseline, there was no signiﬁcant difference in
the arterial baroreﬂex sensitivity between the two
groups (control group: 6.0± 2.9ms/mm Hg vs.
combination group: 6.0± 2.9ms/mmHg, p = 0.95).
Arterial baroreﬂex sensitivity did not change after
4 weeks in the control group (from 6.0± 2.9 to
6.3± 2.6ms/mmHg, p = 0.50), but increased signiﬁ-
cantly from 6.0± 2.0 to 10.1± 2.6ms/mmHg in the
combination group (p < 0.05).
Cardiopulmonary baroreﬂex control of
MSNA
Fig. 3 demonstrates typical arterial pressure,
electrocardiogram, MSNA, and central venous pres-
sure responses during low body negative pressure
obtained from one patient in each group. Low
body negative pressure caused a change in cen-
tral venous pressure without a signiﬁcant change
in arterial pressure. Low body negative pressure
reduced central venous pressure by 3.5± 0.5mmHg
in the control group and by 3.4± 0.8mmHg in
Figure 3 Typical tracings from one subject at control
and during low body negative pressure.
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tastolic dimension; LVDs, LV systolic dimension; LAD, left atrial
R, mitral regurgitation.
he combination group. After 4 weeks, low body
egative pressure resulted in a similar reduction
n central venous pressure in both groups. Fig. 4
hows the changes in the cardiopulmonary barore-
ex control of MSNA before and after 4 weeks of
reatment. At baseline, there was no signiﬁcant
ifference in cardiopulmonary baroreﬂex control
f MSNA between the two groups (control group
7.6± 10.9% vs. combination group 15.8± 12.2%;
= 0.75). Cardiopulmonary baroreﬂex control of
SNA did not change after 4 weeks in the con-
rol group (17.6± 10.9 to 14.9± 13.8%; p = 0.32),
ut increased signiﬁcantly from 15.8± 12.2 to
2.0± 26.7% in the combination group (p < 0.05).
iscussion
his study demonstrated that arterial baroreﬂex
ensitivity and cardiopulmonary baroreﬂex control
f MSNA were augmented after combined therapy in
atients with LV dysfunction. In addition, according
o direct measurement of sympathetic nerve activ-
ty with microneurography, 4 weeks administration
f combined therapy was accompanied by a signiﬁ-
ant reduction of sympathetic nerve activity. These
ndings indicate that the combined valsartan and
CE inhibitor therapy exerts sympathoinhibitory
ffects coupled with improved baroreﬂex function
n patients with LV dysfunction.
Both arterial and cardiopulmonary baroreﬂexes
ormally exert tonic restraint over sympathetic
utﬂow. Experiments in both humans and animals
ave revealed marked impairment of baroreﬂexes
n heart failure [15—18]. The technique used in the
resent study — lower body negative pressure —
auses a change in central venous pressure with-
ut a signiﬁcant change in arterial pressure, thus
solating the two sets of reﬂexes.
Both ACE inhibitors and ARBs decrease arte-
ial and cardiac ﬁlling pressures. Our data show
hat combined therapy caused a small, but not
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tigure 4 Changes in cardiopulmonary baroreﬂex control
ympathetic nerve activity.
tatistically signiﬁcant, fall in resting arterial
lood pressure in patients with LV dysfunction.
espite this fall in resting arterial blood pressure,
ombined therapy decreased directly measured
esting sympathetic activity, which suggests that
he sympathoinhibitory effect of combined ther-
py was not due to hemodynamic improvement.
revious studies have suggested that blockade of
he renin—angiotensin system by ARBs can lower
ympathetic nerve activity and improve baroreﬂex
ontrol of heart rate and sympathetic outﬂow in
nimals with heart failure [19,20]. Our data are
onsistent with those observations and extend
hese previous ﬁndings by showing that combined
herapy decreases sympathetic nerve activity
easured directly in patients with LV dysfunction.
ecause this is accompanied by augmented barore-
exes control of sympathetic outﬂow, it is possible
hat the improvement in baroreﬂexes could be the
echanism by which combined therapy leads to
ympathoinhibitory effects. Moreover, ARBs might
irectly decrease central sympathetic tone since
here is a high concentration of AT1 receptors
n the rostral ventrolateral medulla, a region
nvolved in modulation of sympathetic vasomotor
one [21]. Considering the fact that ARBs pass
he blood—brain barrier more easily than ACE
nhibitors [22], this may be another mechanism
ccounting for the reduction in sympathetic nerve
ctivity after combined therapy. In addition, ARBs
ight decrease norepinephrine release from atria
y acting on AT1 receptors [23].
r
i
sSNA. ACE, angiotensin-converting enzyme; MSNA, muscle
Our study does not clarify the mechanisms
y which combined therapy restores baroreﬂexes’
estraint on sympathetic drive. This mechanism
ay be causally linked to elevated central
ngiotensin II. Increases in central angiotensin II
ave been shown to increase sympathetic outﬂow
nd blunt baroreﬂex responses [24,25]. Indeed,
CE inhibition eliminates angiotensin II stimulatory
ffects of the central nervous system by blocking
ts generation. Compared with ACE inhibition where
nhibition of angiotensin II formation is incom-
lete because high concentrations of angiotensin
to angiotensin II formation occurs through non-
CE pathways, ARBs more completely inhibit the
ction of angiotensin II. Therefore, blockade of
T1 receptors somewhere in the central barore-
ex pathway is most likely responsible for the
mprovement in baroreﬂex function after combined
herapy.
Previous studies have shown that the valsartan
as beneﬁcial hemodynamic and hormonal effects
n patients with heart failure taking standard doses
f ACE inhibitors [26]. Furthermore, greater effec-
iveness of the valsartan was reported in those
n the lower ACE inhibition dose at baseline in
he Valsartan Heart Failure Trial [27]. Therefore,
he doses of enalapril and valsartan we used in
his study would seem sufﬁcient to inhibit the
enin—angiotensin system.
In conclusion, combined valsartan and ACE
nhibitor therapy improved arterial baroreﬂex sen-
itivity and cardiopulmonary baroreﬂex control
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of MSNA in patients with LV dysfunction. This
improvement in baroreﬂexes leads to a reduction
in sympathetic nerve activity.
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